[299 Pages Report] The worldwide pericarditis treatment market is likely to be worth US$ 3.60 Billion in 2022, and is anticipated to grow at a CAGR of 5.24% during the projected period, reaching US$ 6 Billion by 2032. The industry is anticipated to grow owing to growing geriatric population. The extensive advancements in the treatment and diagnosis of cardiovascular diseases will drive the pericarditis drugs market to exponential growth. Furthermore, advancements in the biologics sector will also provide expansive growth prospects between 2022 and 2032.
| Report Attribute | Details |
|---|---|
| Estimated Base Year Value (2021) | US$ 3.35 Billion |
| Expected Market Value (2022) | US$ 3.60 Billion |
| Anticipated Forecast Value (2032) | US$ 6 Billion |
| Projected Growth Rate (2022 to 2032) | 5.24% CAGR |
Research and development activities are critical to the expansion of the pericarditis drugs market. Because of the increased use of these drugs, the players have focused their efforts on research. The activities aid in the development of new formulations, which significantly increase the growth opportunities in the pericarditis drugs market. All of these factors point to the pericarditis treatment market expanding. Strategic partnerships are critical in the pericarditis treatment market. The players are engaging in mergers and acquisitions to strengthen their position in the pericarditis treatment market, ultimately sowing the seeds of development.
Pericarditis is a cardiovascular disease characterized by excrescence of the heart's pericardium wall. The chief cause of pericardium disease is pericardium wall inflammation, which is usually caused by a viral infection. Other causes of pericarditis include renal failure, bacterial infections, and the use of certain medications such as procainamide.
Shortness of breath, fatigue, rapid or abnormal heart rhythms, and chest pain are all typical symptoms of pericarditis. Global pericarditis treatment includes both therapeutic and surgical measures. Acute pericarditis can be treated with pain and inflammation medications such as aspirin and ibuprofen. Several antifungal medications are prescribed depending on the cause of the pericarditis disease, and these are projected to generate the most revenue in the pericarditis treatment market.
Anti-inflammatory drugs such as colchicine are prescribed for pericarditis treatment in cases of chronic or recurrent pericarditis. If the patient with pericarditis disease does not respond to anti-inflammatory medications, corticosteroids such as prednisone are prescribed. Aside from medications, other surgical methods of treatment in the pericarditis treatment market are required in patients, especially when all other medical treatments fail.
In addition to that with multiple medication options for disease treatment available, the pericarditis treatment market may see new opportunities. The introduction of biologics, the adoption of dual therapy, the greater prevalence of idiopathic pericarditis, and product approvals are driving the anticipated growth of the pericarditis treatment market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rising prevalence of cardiovascular diseases around the world is a major growth driver for the Global Pericarditis Treatment Market. The growing geriatric population has also been influencing the pericarditis treatment market. Acute pericarditis is the most common disease in several clinical settings, according to Cureus, an open access medical journal for a new generation of doctors and patients.
Acute pericarditis has been reported to affect between 0.1 and 0.2% of hospitalized patients, with 5% of patients admitted to the emergency department with non-ischemic chest pain. Furthermore, cardiovascular diseases kill 17.9 million people worldwide each year, accounting for an estimated 31% of all deaths. Low- and middle-income countries account for more than 75% of cardiovascular deaths. The use of dual therapy to treat idiopathic pericarditis is a major factor driving the global pericarditis treatment market. Aspirin is traditionally used as a monotherapy to treat acute pericarditis.
Furthermore, increased smoking, alcohol consumption, and lifestyle changes are major contributors to the rise in cardiovascular diseases, as well as the pericarditis treatment market. More emphasis on the prevention and treatment of cardiovascular diseases in low- and middle-income countries is expected to drive the growth of the Pericarditis treatment market.
As a result of the increased prevalence of idiopathic pericarditis with repeated episodes, the use of dual therapy, such as aspirin with colchicine, is expected to rise. Aspirin is traditionally used as a monotherapy to treat acute pericarditis. However, clinical trials for dual therapy with the combination of two drugs - aspirin and colchicine - for the treatment of pericarditis are underway. When compared to conventional monotherapy, the results show that combination therapy is more effective in reducing pericarditis recurrence.
As a result of the increased prevalence of idiopathic pericarditis with repeated episodes, the use of dual therapy, such as aspirin with colchicine, is expected to rise. However, the presence of misbranded drugs, surgical intervention, and stringent government rules and regulations are expected to impede the growth of the global pericarditis drugs market in the upcoming years. Moreover, rising healthcare costs are also expected to drive the global pericarditis treatment market.
Principal Consultant
Because of its large population and high prevalence of cardiovascular diseases, Asia Pacific is expected to have a significant revenue share in the global pericarditis treatment market.
The Asia Pacific pericarditis treatment market is anticipated to expand rapidly during the forecast period, owing to an increase in the number of cardiac surgeries, an uptick in patients with cardiovascular disorders, and broadening health care infrastructure.
According to Future Market Insights, owing to its large network of medical and high-quality healthcare infrastructure, North America is expected to hold the largest share of the Pericarditis Treatment Market. Because North America has a large number of clinical research laboratories, it is anticipated to spur pericarditis treatment market.
Furthermore, this is due to the increasing amount of people diagnosed with cardiac disorders, as well as significant R&D and health-care spending. Furthermore, increased awareness of cardiovascular disorders is expected to drive market growth in North America.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the key participants present in the global Pericarditis Treatment market include Pfizer Inc., Bayer AG, PerkinElmer Inc., ALLERGAN, Lincoln Pharmaceuticals Ltd., Unicure India Pvt. Ltd., Zydus Cadila Healthcare Ltd., Twilight Mercantiles Pvt. Ltd., Aasraw Biochemical Technology Co.ltd, Sun Pharmaceutical Industries Ltd. among others.
As a result of the presence of a larger number of international and local players, the worldwide pericarditis drugs market is moderately competitive.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.24% from 2022 to 2032 |
| Market Value for 2022 | US$ 3.6 Billion |
| Market Value for 2032 | US$ 6 Billion |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022- to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global Pericarditis Treatment market to expand at a 5.24% value CAGR by 2032
Asia Pacific is expected to be the most opportunistic Pericarditis Treatment market, expanding at a 5% CAGR during the forecast period.
Pfizer Inc., Bayer AG, PerkinElmer Inc., ALLERGAN, Lincoln Pharmaceuticals Ltd., Unicure India Pvt. Ltd., Zydus Cadila Healthcare Ltd. and Twilight Mercantiles Pvt. Ltd., are some prominent pericarditis treatment manufacturers
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. Value Chain Analysis 3.5.1. Profit Margin Analysis 3.5.2. Service Providers 3.6. PESTLE and Porter’s Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global Pericarditis Treatment Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Disease Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Type, 2022-2032 5.3.1. Acute Pericarditis 5.3.2. Chronic Pericarditis 5.3.3. Recurrent Pericarditis 5.3.4. Idiopathic Pericarditis 5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Disease Type, 2022-2032 6. Global Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Treatment 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2022-2032 6.3.1. Therapeutics 6.3.2. Nonsteroidal Anti-inflammatory Drugs 6.3.3. Antibiotic/Antifungal Medication 6.3.4. Corticosteroids 6.3.5. Surgery 6.3.6. Pericardiectomy 6.3.7. Pericardiocentesis 6.3.8. Pericardiotomy 6.4. Y-o-Y Growth Trend Analysis By Treatment, 2017-2021 6.5. Absolute $ Opportunity Analysis By Treatment, 2022-2032 7. Global Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By End Users 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) Analysis By End Users, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End Users, 2022-2032 7.3.1. Hospitals 7.3.2. Clinics 7.3.3. Ambulatory Surgical Centers 7.3.4. Academic & Research Institutes 7.4. Y-o-Y Growth Trend Analysis By End Users, 2017-2021 7.5. Absolute $ Opportunity Analysis By End Users, 2022-2032 8. Global Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021 8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia & Pacific 8.3.6. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Disease Type 9.2.3. By Treatment 9.2.4. By End Users 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Disease Type 9.3.3. By Treatment 9.3.4. By End Users 9.4. Key Takeaways 10. Latin America Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Mexico 10.2.1.2. Brazil 10.2.1.3. Rest of Latin America 10.2.2. By Disease Type 10.2.3. By Treatment 10.2.4. By End Users 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Disease Type 10.3.3. By Treatment 10.3.4. By End Users 10.4. Key Takeaways 11. Europe Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. U.K. 11.2.1.5. Spain 11.2.1.6. BENELUX 11.2.1.7. Russia 11.2.1.8. Rest of Europe 11.2.2. By Disease Type 11.2.3. By Treatment 11.2.4. By End Users 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Disease Type 11.3.3. By Treatment 11.3.4. By End Users 11.4. Key Takeaways 12. East Asia Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Disease Type 12.2.3. By Treatment 12.2.4. By End Users 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Disease Type 12.3.3. By Treatment 12.3.4. By End Users 12.4. Key Takeaways 13. South Asia & Pacific Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. India 13.2.1.2. ASEAN 13.2.1.3. Australia and New Zealand 13.2.1.4. Rest of South Asia & Pacific 13.2.2. By Disease Type 13.2.3. By Treatment 13.2.4. By End Users 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Disease Type 13.3.3. By Treatment 13.3.4. By End Users 13.4. Key Takeaways 14. MEA Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. Turkey 14.2.1.3. South Africa 14.2.1.4. Rest of MEA 14.2.2. By Disease Type 14.2.3. By Treatment 14.2.4. By End Users 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Disease Type 14.3.3. By Treatment 14.3.4. By End Users 14.4. Key Takeaways 15. Key Countries Pericarditis Treatment Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2021 15.1.2.1. By Disease Type 15.1.2.2. By Treatment 15.1.2.3. By End Users 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2021 15.2.2.1. By Disease Type 15.2.2.2. By Treatment 15.2.2.3. By End Users 15.3. Mexico 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2021 15.3.2.1. By Disease Type 15.3.2.2. By Treatment 15.3.2.3. By End Users 15.4. Brazil 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2021 15.4.2.1. By Disease Type 15.4.2.2. By Treatment 15.4.2.3. By End Users 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2021 15.5.2.1. By Disease Type 15.5.2.2. By Treatment 15.5.2.3. By End Users 15.6. Italy 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2021 15.6.2.1. By Disease Type 15.6.2.2. By Treatment 15.6.2.3. By End Users 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2021 15.7.2.1. By Disease Type 15.7.2.2. By Treatment 15.7.2.3. By End Users 15.8. U.K. 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2021 15.8.2.1. By Disease Type 15.8.2.2. By Treatment 15.8.2.3. By End Users 15.9. Spain 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2021 15.9.2.1. By Disease Type 15.9.2.2. By Treatment 15.9.2.3. By End Users 15.10. BENELUX 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2021 15.10.2.1. By Disease Type 15.10.2.2. By Treatment 15.10.2.3. By End Users 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2021 15.11.2.1. By Disease Type 15.11.2.2. By Treatment 15.11.2.3. By End Users 15.12. China 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2021 15.12.2.1. By Disease Type 15.12.2.2. By Treatment 15.12.2.3. By End Users 15.13. Japan 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2021 15.13.2.1. By Disease Type 15.13.2.2. By Treatment 15.13.2.3. By End Users 15.14. South Korea 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2021 15.14.2.1. By Disease Type 15.14.2.2. By Treatment 15.14.2.3. By End Users 15.15. India 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2021 15.15.2.1. By Disease Type 15.15.2.2. By Treatment 15.15.2.3. By End Users 15.16. ASEAN 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2021 15.16.2.1. By Disease Type 15.16.2.2. By Treatment 15.16.2.3. By End Users 15.17. Australia and New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2021 15.17.2.1. By Disease Type 15.17.2.2. By Treatment 15.17.2.3. By End Users 15.18. GCC Countries 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2021 15.18.2.1. By Disease Type 15.18.2.2. By Treatment 15.18.2.3. By End Users 15.19. Turkey 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2021 15.19.2.1. By Disease Type 15.19.2.2. By Treatment 15.19.2.3. By End Users 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2021 15.20.2.1. By Disease Type 15.20.2.2. By Treatment 15.20.2.3. By End Users 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Disease Type 16.3.3. By Treatment 16.3.4. By End Users 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Pfizer Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Bayer AG 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. PerkinElmer Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. ALLERGAN 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Lincoln Pharmaceuticals Ltd. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Unicure India Pvt. Ltd. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Zydus Cadila Healthcare Ltd. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. Aasraw Biochemical Technology Co.ltd 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Sun Pharmaceutical Industries Ltd 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Pericarditis Treatment Market
